BioSig subsidiary NeuroClear acquired license for a broad-spectrum anti-viral agent that may treat COVID-19
On Mar. 24, 2020, BioSig Technologies announced that its majority-owned subsidiary NeuroClear Technologies, acquired the rights to develop a novel pharmaceutical to treat Coronavirus Disease 2019 (COVID-19).
Tags:
Source: BioSig Technologies, Inc.
Credit:
